about
Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissueControl of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alphaRegulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and betaA PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesisEvaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey PharmacokineticsLXR signaling couples sterol metabolism to proliferation in the acquired immune response.Rational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant.Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.Prospective Design of Anti-Transferrin Receptor Bispecific Antibodies for Optimal Delivery into the Human Brain.Evaluation of Fluorophotometry to Assess the Vitreal Pharmacokinetics of Protein Therapeutics.Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,Erythropoietin (Epo) and EpoR expression and 2 waves of erythropoiesis.Peroxisomal proliferator-activated receptor alpha deficiency diminishes insulin-responsiveness of gluconeogenic/glycolytic/pentose gene expression and substrate cycle flux.Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).Relative Target Affinities of T Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model.Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain.Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonistsDiscovery of structurally novel, potent and orally efficacious GPR119 agonistsDiscovery of short-course antiwolbachial quinazolines for elimination of filarial worm infections
P50
Q24677042-B3458753-0705-441A-A16F-31227FD0FCF6Q24683359-D82E8CD6-C8AD-4089-9FE1-D9E8B0414B15Q28198291-EEF5B70F-D8AA-4E21-9403-906549DB553CQ28199913-77E63265-8592-4199-AD0D-9CC3238D613CQ36444225-DEB4EC4B-ECC4-4C7A-9C18-B248D149142BQ37061238-08A24C78-280C-48DC-9779-62455B23FE41Q37346963-85C10579-F045-4FC4-B9D6-E5611985A58DQ38308213-9145E0AC-951E-48E1-B1C8-05B9177ECB6BQ39684687-4BC4EA13-F99C-4BAB-A482-F0CD22454F19Q40380005-75E69FC4-C495-4024-BB5B-22D753D315CAQ42710837-6BD07E38-96D5-40EB-80C6-C737DE56D2F8Q43718528-F6316F02-EDC8-4C8D-978A-FD9C87A4639EQ44690099-F1BCA30E-EAEA-404A-864F-C8B1BBE2A9C8Q46072823-77EE95DD-1E53-4B6F-978F-C26EC61EED16Q48535042-59AA7417-C320-436D-AF0A-32AA104ABB44Q48944242-7B7F9235-0010-4190-8835-71D4C300868FQ86126368-BC9F0E98-8524-459E-ACF4-46E24BDA6275Q87722112-E14456E2-FDA6-4413-AAEB-8584DECA6342Q91863242-90DDB49F-EE90-464F-A039-D3586837CFBA
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sean Joseph
@ast
Sean Joseph
@en
Sean Joseph
@es
Sean Joseph
@nl
type
label
Sean Joseph
@ast
Sean Joseph
@en
Sean Joseph
@es
Sean Joseph
@nl
prefLabel
Sean Joseph
@ast
Sean Joseph
@en
Sean Joseph
@es
Sean Joseph
@nl
P106
P1153
7202290415
P31
P496
0000-0002-2602-8517